| MeSH term | MeSH ID | Detail |
|---|---|---|
| Scorpion Stings | D065008 | 1 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| End Stage Liver Disease | D058625 | 1 associated lipids |
| Candidiasis, Invasive | D058365 | 2 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Central Serous Chorioretinopathy | D056833 | 1 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
| Pancreatitis, Graft | D055589 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Primary Graft Dysfunction | D055031 | 1 associated lipids |
| Idiopathic Interstitial Pneumonias | D054988 | 1 associated lipids |
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Dysuria | D053159 | 1 associated lipids |
| Nocturia | D053158 | 1 associated lipids |
| Delayed Graft Function | D051799 | 2 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Lymphohistiocytosis, Hemophagocytic | D051359 | 1 associated lipids |
| Granulomatosis, Orofacial | D051261 | 2 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Dyslipidemias | D050171 | 7 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Hepatic Insufficiency | D048550 | 1 associated lipids |
| Colitis, Collagenous | D046729 | 1 associated lipids |
| Protoporphyria, Erythropoietic | D046351 | 1 associated lipids |
| Coproporphyria, Hereditary | D046349 | 1 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Intestinal Volvulus | D045822 | 1 associated lipids |
| Cholecystolithiasis | D041761 | 2 associated lipids |
| Mastocytosis, Cutaneous | D034701 | 1 associated lipids |
| Hypoalbuminemia | D034141 | 1 associated lipids |
| Hyperuricemia | D033461 | 4 associated lipids |
| Papillomavirus Infections | D030361 | 4 associated lipids |
| Denys-Drash Syndrome | D030321 | 1 associated lipids |
| Pulmonary Disease, Chronic Obstructive | D029424 | 16 associated lipids |
| Polyomavirus Infections | D027601 | 1 associated lipids |
| Coronary Stenosis | D023921 | 6 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Brachial Plexus Neuritis | D020968 | 2 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Hypoxia-Ischemia, Brain | D020925 | 22 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Nervous System Autoimmune Disease, Experimental | D020721 | 3 associated lipids |
| Stroke | D020521 | 32 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Ventricular Remodeling | D020257 | 28 associated lipids |
| Infarction, Middle Cerebral Artery | D020244 | 35 associated lipids |
| Optic Nerve Injuries | D020221 | 4 associated lipids |
| Facial Nerve Injuries | D020220 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Nocturnal Myoclonus Syndrome | D020189 | 1 associated lipids |
| Sleep Apnea, Central | D020182 | 1 associated lipids |
| Citrullinemia | D020159 | 1 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Epstein-Barr Virus Infections | D020031 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Miller Fisher Syndrome | D019846 | 1 associated lipids |
| Hepatitis C, Chronic | D019698 | 12 associated lipids |
| Hepatitis B, Chronic | D019694 | 4 associated lipids |
| Hepatitis, Autoimmune | D019693 | 1 associated lipids |
| Neurodegenerative Diseases | D019636 | 32 associated lipids |
| Intracranial Hypertension | D019586 | 4 associated lipids |
| Dermatitis, Perioral | D019557 | 4 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Endotoxemia | D019446 | 27 associated lipids |
| Oral Ulcer | D019226 | 1 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Fasciitis, Necrotizing | D019115 | 1 associated lipids |
| Postoperative Hemorrhage | D019106 | 7 associated lipids |
| Multiple Endocrine Neoplasia Type 2a | D018813 | 1 associated lipids |
| Anemia, Iron-Deficiency | D018798 | 6 associated lipids |
| Encephalitis, Viral | D018792 | 3 associated lipids |
| Hypoplastic Left Heart Syndrome | D018636 | 1 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Lichen Sclerosus et Atrophicus | D018459 | 2 associated lipids |
| Vasculitis, Leukocytoclastic, Cutaneous | D018366 | 5 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Angiofibroma | D018322 | 2 associated lipids |
| Cervical Intraepithelial Neoplasia | D018290 | 1 associated lipids |
| Seminoma | D018239 | 2 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schmidt LE et al. | Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. | 2003 | Transplantation | pmid:12883193 |
| Troppmann C et al. | Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. | 2003 | Transplantation | pmid:12883205 |
| Pech T et al. | Combination therapy of tacrolimus and infliximab reduces inflammatory response and dysmotility in experimental small bowel transplantation in rats. | 2012 | Transplantation | pmid:22167049 |
| Ellis D et al. | Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10532541 |
| Ciancio G et al. | Randomized trial of three induction antibodies in kidney transplantation: long-term results. | 2014 | Transplantation | pmid:24477186 |
| Reutzel-Selke A et al. | Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. | 2003 | Transplantation | pmid:12811235 |
| Molano RD et al. | Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. | 2003 | Transplantation | pmid:12811239 |
| Trancassini M et al. | Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. | 2001 | Transplantation | pmid:11707748 |
| Waldman WJ et al. | Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. | 2001 | Transplantation | pmid:11707749 |
| Woodle ES et al. | FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. | 1993 | Transplantation | pmid:7504346 |
| Jindal RM et al. | Effect of deoxyspergualin on the endocrine function of the rat pancreas. | 1993 | Transplantation | pmid:7504347 |
| Eberhard OK et al. | How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. | 1996 | Transplantation | pmid:8629294 |
| Millis JM et al. | Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. | 1996 | Transplantation | pmid:8629298 |
| Sheiner PA et al. | Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. | 1997 | Transplantation | pmid:9355846 |
| van Hooff JP | Pneumocystis carinii pneumonia after renal transplantation. | 1997 | Transplantation | pmid:9158038 |
| Conrotto D et al. | Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. | 2006 | Transplantation | pmid:17060865 |
| Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
| Kitayama T et al. | Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. | 2003 | Transplantation | pmid:12605126 |
| Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
| Egidi MF and Gaber AO | Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. | 2003 | Transplantation | pmid:12605133 |
| Cassuto E et al. | Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study. | 2016 | Transplantation | pmid:27653227 |
| Stojanovic J et al. | Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation. | 2017 | Transplantation | pmid:27463537 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. | 2002 | Transplantation | pmid:12490779 |
| Tokita D et al. | High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. | 2008 | Transplantation | pmid:18301333 |
| Ekberg H et al. | The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. | 2009 | Transplantation | pmid:19424036 |
| Jugie M et al. | Study of the impact of liver transplantation on the outcome of intestinal grafts in children. | 2006 | Transplantation | pmid:16612274 |
| Sommerer C et al. | Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. | 2010 | Transplantation | pmid:20463649 |
| Froud T et al. | Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. | 2008 | Transplantation | pmid:19104407 |
| Curran CF et al. | Acute overdoses of tacrolimus. | 1996 | Transplantation | pmid:8932293 |
| MacDonald AS | Management strategies for nephrotoxicity. | 2000 | Transplantation | pmid:10910262 |
| Reyes J et al. | Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. | 2000 | Transplantation | pmid:10910279 |
| Xu H et al. | Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance. | 2013 | Transplantation | pmid:23250336 |
| Higgins RM et al. | Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10836393 |
| Garton T | Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. | 2002 | Transplantation | pmid:12352898 |
| Yamauchi A et al. | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. | 2002 | Transplantation | pmid:12352921 |
| Woodle ES et al. | Liver transplantation in the first three months of life. | 1998 | Transplantation | pmid:9753340 |
| Radkowski M et al. | Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9753352 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. | 2004 | Transplantation | pmid:14742989 |
| van Hooff JP et al. | Tacrolimus and posttransplant diabetes mellitus in renal transplantation. | 2005 | Transplantation | pmid:15940032 |
| Mourer JS et al. | Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. | 2013 | Transplantation | pmid:23715049 |
| Gaber AO et al. | Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. | 2013 | Transplantation | pmid:23715050 |
| Warty V et al. | FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. | 1988 | Transplantation | pmid:2458643 |
| Günther M et al. | Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. | 2001 | Transplantation | pmid:11233913 |
| Ekberg H et al. | Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. | 2011 | Transplantation | pmid:21562449 |
| Rezeig MA et al. | Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. | 1997 | Transplantation | pmid:9175820 |
| Hricik DE et al. | Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2003 | Transplantation | pmid:14508357 |
| Foster RD et al. | Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. | 2003 | Transplantation | pmid:14508367 |
| Uemoto S et al. | Experience with FK506 in living-related liver transplantation. | 1993 | Transplantation | pmid:7679528 |
| Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |
| Mor E et al. | Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7513098 |